PetVivo Holdings, Inc.
PETV Healthcare Medical Devices
PetVivo Holdings, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, up 0.80% from fiscal 2025. In the quarter to June 2026, revenue grew 13.5%, EPS grew 44.4% and free cash flow grew 40.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow PETV
PetVivo Holdings, Inc. (PETV) Piotroski F-score
PetVivo Holdings, Inc.'s Piotroski F-score for fiscal 2026 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 3 | (1.00) |
| FY2025 | 4 | 0.00 |
| FY2024 | 4 | 1.00 |
| FY2023 | 3 | (2.00) |
| FY2022 | 5 | 0.00 |
| FY2018 | 5 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (168.43%) | (134.88%) | Fail | 0 |
| Positive operating cash flow | (6.11m) | (5.32m) | Fail | 0 |
| Rising return on assets | (168.43%) | (134.88%) | Fail | 0 |
| Cash flow above net income | 4.77m | 3.08m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 1.35 | 1.30 | Pass | 1 |
| No new shares issued | 30,154,600 | 20,491,400 | Fail | 0 |
| Rising gross margin | 66.12% | 87.85% | Fail | 0 |
| Rising asset turnover | 0.18 | 0.18 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| BTCY Biotricity Inc. compare | 5 |
| HSCS HeartSciences Inc. compare | 4 |
| IRIX IRIDEX Corporation compare | 4 |
| LFWD Lifeward Ltd. compare | 4 |
| PETV PetVivo Holdings, Inc. | 3 |
| CTSO Cytosorbents Corporation compare | 3 |
| ALUR Allurion Technologies, Inc. compare | 2 |
| SINT SINTX TECHNOLOGIES, INC. compare | 2 |
| RBOT Vicarious Surgical Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover